116 results on '"Kyle A Weant"'
Search Results
2. Optimizing Status Epilepticus Management in the Emergency Department
- Author
-
Kyle A. Weant and Haili Gregory
- Subjects
Emergency Medicine ,Emergency Nursing - Published
- 2023
3. Development of an emergency medicine pharmacy intensity score tool
- Author
-
Kyle A, Weant, Nicole M, Acquisto, Cassandra R, Doyno, Haili, Gregory, Megan A, Rech, Cory J, Schlobohm, Andrew P, Smith, and Kimberly J, Won
- Subjects
Pharmacology ,Health Policy - Abstract
In an effort to expedite the publication of articles, AJHP is posting manuscripts online as soon as possible after acceptance. Accepted manuscripts have been peer-reviewed and copyedited, but are posted online before technical formatting and author proofing. These manuscripts are not the final version of record and will be replaced with the final article (formatted per AJHP style and proofed by the authors) at a later time.Emergency medicine pharmacists (EMPs) have been demonstrated to have a positive impact on patient outcomes in a variety of clinical scenarios in the emergency department (ED), yet their distribution across the nation is suboptimal. An emergency medicine pharmacy intensity score tool (EMPIST) would not only facilitate the quantification of EMP staffing needs and ideal resource deployment times, but would also allow practitioners to triage patient care activities. The purpose of this investigation was to develop an EMPIST and evaluate its relationship to EMP activities.This was a multicenter, prospective, observational analysis of an EMPIST developed by practicing EMPs. EMPs prospectively documented their clinical activities during usual care for patients in their ED. Spearman's rank-order correlation was used to determine any correlation between the EMPIST and pharmacist activities.In total, 970 EMP activities and 584 EMPIST items were documented in 352 patients by 7 EMPs across 7 different EDs. The most commonly documented EMP interventions performed were bedside monitoring (12.7%), initiation of nonantimicrobial therapy (12.6%), and antimicrobial therapy initiation and streamlining (10.6%). The total EMPIST was found to significantly correlate with EMP activities, and this correlation was consistent across both "diagnostic/presentation" and "medication" items (P0.001 for all comparisons).The EMPIST significantly correlated with EMP activities, with consistent correlation across all subgroups. Its utilization has the potential to enhance bedside clinical practice and optimize the deployment of limited EMP services. Additional investigations are needed to examine the validity of this tool and identify any relationship it may have to patient outcomes.
- Published
- 2022
4. Recommendations for nonantidote medications needed in the emergency department during a mass casualty incident
- Author
-
Haili Gregory, Raniah Aljadeed, Dharati Desai, Faisal Syed Minhaj, Andrew Posen, Megan A Rech, Andrew P Smith, Kyle A Weant, Kimberly J Won, and David E Zimmerman
- Subjects
Pharmacology ,Health Policy - Published
- 2023
5. Guidance for emergency medicine pharmacists to improve care for people with opioid use disorder
- Author
-
Abby M. Bailey, Jordan R. Kelsch, Regan A. Baum, Elise L. Metts, and Kyle A. Weant
- Subjects
Opioid epidemic ,medicine.medical_specialty ,business.industry ,Emergency medicine ,Pharmaceutical Science ,Medicine ,Pharmacology (medical) ,Opioid use disorder ,Pharmacy ,business ,medicine.disease ,Opiate overdose - Published
- 2021
6. Risk Factors for Antibiotic Resistant Urinary Pathogens in Patients Discharged From the Emergency Department
- Author
-
Gregory A. Hall, Kyle A. Weant, Stephanie L. Barré, Erin R. Weeda, and Andrew J. Matuskowitz
- Subjects
Pharmacology ,medicine.medical_specialty ,Antibiotic resistance ,business.industry ,Urinary system ,Emergency medicine ,medicine ,Pharmacology (medical) ,In patient ,Pharmacy ,Emergency department ,business - Abstract
Purpose: Urinary tract infections (UTIs) are one of the most common indications for antimicrobial use in the emergency department (ED). Appropriate empiric selection is crucial to ensure optimal care while limiting broad-spectrum antibiotic use. The primary objective of this study was to evaluate the relationship between patient-specific risk factors and drug resistant urinary pathogens in patients discharged from the ED and followed by Emergency Medicine Pharmacists (EMPs). Methods: This was a single-center, retrospective chart review of adult (≥18 years old) patients with positive urine cultures discharged from the ED. The association between risk factors and pathogen resistance to ≥1 classes of antibiotics was evaluated using multivariate logistic regression. Risk factors included the following: hospitalization within the previous 30 days, intravenous antibiotic use within 90 days, diabetes, clinical atherosclerotic cardiovascular disease, psychiatric disorder, dementia, current antibiotic use for any indication, previous lifetime history of UTIs, indwelling or intermittent catheterization, hemodialysis, previous lifetime history of a urologic procedure, urinary tract abnormality, immunosuppressive disease or medications, current residence in a nursing or rehabilitation facility, and history of a multidrug resistant organism (MDRO). Results: A total of 1018 patients were included. There was an increase in the odds of antibiotic resistance in patients with cystitis and ≥2 risk factors (Odds Ratio [OR] = 1.70, 95% CI = 1.24-2.32). In those with pyelonephritis, there was a non-significant increase in the odds of resistance for those with ≥2 risk factors (OR = 1.83, 95% CI = 0.98-3.42). Patients with pyelonephritis discharged on inappropriate antibiotics were more likely to return to the ED within 30 days ( P = .03). Conclusions: For patients with cystitis discharged from the ED, those with ≥2 patient-specific risk factors had significantly increased odds of antibiotic resistance. Patients with pyelonephritis, but not cystitis, who were discharged on inappropriate antibiotics were more likely to return to the ED within 30 days. In conjunction with an EMP culture follow-up program, the identification of risk factors for antimicrobial resistance can be used to design more patient-specific empiric antibiotic selections.
- Published
- 2021
7. Intravenous insulin for the management of non-emergent hyperglycemia in the emergency department
- Author
-
Andrew J. Matuskowitz, Lauren J. Koscal, Kyle A. Weant, and Erin R. Weeda
- Subjects
Adult ,Blood Glucose ,Male ,medicine.medical_specialty ,medicine.medical_treatment ,Pharmacy ,Hypoglycemia ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,Humans ,Hypoglycemic Agents ,Insulin ,Medicine ,Adverse effect ,Retrospective Studies ,business.industry ,Trauma center ,030208 emergency & critical care medicine ,General Medicine ,Emergency department ,Length of Stay ,Middle Aged ,medicine.disease ,Hypokalemia ,Hyperglycemia ,Emergency Medicine ,Regular insulin ,Administration, Intravenous ,Female ,medicine.symptom ,Emergency Service, Hospital ,business - Abstract
There is currently no consensus regarding the necessity of emergency department (ED) glucose reduction to manage hyperglycemia in patients presenting without a hyperglycemic emergency. Known consequences of intravenous (IV) insulin administration include hypoglycemia, hypokalemia, and increased ED length of stay. The primary objective of this study was to assess the impact of IV regular insulin on glucose reduction and ED length of stay in patients presenting to the ED with non-emergent hyperglycemia. Secondary objectives included the characterization of potential adverse events.This was a retrospective, observational study of patients ≥18 years who received IV regular insulin and were discharged from the ED at a large academic Trauma Center. Univariate and multivariable regression analyses were utilized to determine if an association existed between IV insulin administration and blood glucose as well as ED length of stay.A total of 405 patients were included in the analysis. An insulin dose5 units was associated with a greater reduction in blood glucose (difference = 37.4 mg/dL; p .001) but no difference in ED length of stay relative to ≤5 units. Furthermore, 7.9% of patients developed hypokalemia and 0.4% developed hypoglycemia.The use of5 units of IV regular insulin for the management of isolated hyperglycemia in the ED was associated with a modest reduction in blood glucose and no difference in ED length of stay compared with those that received ≤5 units. However, use of IV insulin for this purpose resulted in a 7.9% occurrence of hypokalemia.
- Published
- 2021
8. Assessment of benzodiazepine dosing strategies for the management of status epilepticus in the emergency department
- Author
-
Kyle A. Weant, Sara Bruner, Ryan Smiley, Stephanie L. Barré, and Gregory A. Hall
- Subjects
Male ,medicine.medical_specialty ,medicine.drug_class ,Status epilepticus ,law.invention ,Benzodiazepines ,03 medical and health sciences ,Status Epilepticus ,0302 clinical medicine ,law ,medicine ,Humans ,Dosing ,Practice Patterns, Physicians' ,Retrospective Studies ,Benzodiazepine ,business.industry ,030208 emergency & critical care medicine ,Lorazepam ,General Medicine ,Guideline ,Emergency department ,Middle Aged ,Intensive care unit ,Emergency medicine ,Emergency Medicine ,Midazolam ,Anticonvulsants ,Female ,medicine.symptom ,Emergency Service, Hospital ,business ,medicine.drug - Abstract
Although guidelines recommend specific benzodiazepine doses for the treatment of generalized convulsive status epilepticus (GCSE), underdosing appears to be common. The purpose of this investigation was to assess benzodiazepine dosing strategies for the initial management of GCSE in patients presenting to the Emergency Department (ED).This was a retrospective review of adult patients who received benzodiazepines in the ED for treatment of GCSE. Characteristics of those achieving seizure cessation following initial benzodiazepine therapy were assessed.222 patients presented to the ED and received 403 doses of benzodiazepines, of which 1.5% conformed with recommendations. First-line therapy was successful in 86.8% of patients with an average dose of 1.6 mg (0.02 mg/kg). No difference in dosing was noted between those experiencing early cessation and those that did not (p = 0.132). Patients experiencing early cessation were significantly less likely to receive further doses, be intubated, or be admitted to the intensive care unit (ICU) or hospital (p 0.05 for all comparisons). Those that received early antiepileptic drug therapy were significantly less likely to receive additional benzodiazepine doses, be intubated, or be admitted to the ICU or hospital (p 0.05 for all comparisons).According to guideline recommendations, there was consistent underdosing of benzodiazepines noted in both prehospital and ED settings. Early seizure cessation and the early receipt of an antiepileptic drug were found to be associated with multiple significant clinical outcomes. Future investigations should explore optimal dosing strategies for benzodiazepines as well as the impact of early antiepileptic drug administration.
- Published
- 2021
9. Possible Delay in Symptomatology of a Methadone Overdose in a Patient Ingesting an Energy Drink and Dextroamphetamine/Amphetamine
- Author
-
Kyle A. Weant and Gregory A. Hall
- Subjects
Pharmacology (medical) - Abstract
Introduction: Methadone is a mu-opioid agonist with a delayed time to peak concentration that requires an extended period of monitoring following an overdose. Available data suggests that the combination of psychostimulants with methadone may augment antinociception and tolerance to opioids. Case Report: A 26-year-old male (83.9 kg) presented to the ED approximately 1 hour after unintentionally ingesting 200-250 mg of liquid methadone and an energy drink, along with 20 mg of dextroamphetamine/amphetamine prior to the event. Vital signs were: blood pressure (BP), 143/91 mmHg; heart rate (HR), 74; respirations (RR), 16; oxygen saturation 95% on room air. His urine drug screen was positive for amphetamines and methadone. Patient was monitored for 4 hours with no change in status and was discharged home. Approximately 26 hours later patient was found cyanotic and apneic. Patient was given 2 mg of naloxone and awoke with normal mental status. On presentation the patient’s vital signs were: BP, 114/70 mmHg; HR, 114; RR 16; oxygen saturation 94% on 3 liters nasal cannula. During his ED stay, he required 2 doses of naloxone secondary to oxygen desaturation and was admitted to the hospital. His repeat urine drug screen was positive for amphetamines and methadone. The patient was discharged the following day. Discussion: This case illustrates an unintentional methadone overdose combined with the intentional ingestion of an energy drink and dextroamphetamine/amphetamine that possibly masked the toxicity for over 24 hrs. Monitoring parameters for methadone overdoses may need re-evaluation in the setting of the co-ingestion of a stimulant.
- Published
- 2022
10. Evaluation of Dosing Strategies of N-acetylcysteine for Acetaminophen Toxicity in Patients Greater than 100 Kilograms: Should the Dosage Cap Be Used?
- Author
-
Sanjay R. Mohan, Kyle A. Weant, Peter Akpunonu, Abby M. Bailey, Mark K. Su, Molly M Howell, Ashley N Webb, LeeAnn Geraghty, Jordan A Woolum, and Regan A. Baum
- Subjects
business.industry ,Cumulative dose ,Health, Toxicology and Mutagenesis ,medicine.medical_treatment ,030208 emergency & critical care medicine ,Toxicology ,Intensive care unit ,Acetaminophen ,law.invention ,03 medical and health sciences ,Regimen ,0302 clinical medicine ,law ,Anesthesia ,medicine ,Original Article ,030212 general & internal medicine ,Antipyretic ,Dosing ,Antidote ,business ,Adverse effect ,medicine.drug - Abstract
INTRODUCTION: Acetaminophen is a commonly used analgesic and antipyretic, with the potential to cause significant injury when ingested in toxic amounts. Although the antidote n-acetylcysteine (NAC) is available, evidence supporting dose recommendations for patients weighing over 100 kg are lacking. We performed a retrospective, multi-center analysis to determine if a capped NAC dosing scheme is similar to a non-capped dosing scheme in patients weighing over 100 kg. METHODS: Between January 2009 and January 2016, we identified patients presenting to 12 different centers who were evaluated for acetaminophen poisoning treatment. Patients must have weighed greater than 100 kg and were evaluated and identified as needing treatment for acetaminophen-related poisoning with NAC. The primary outcome was occurrence of hepatic injury, defined as an AST or ALT ≥ 100 IU/L. Secondary endpoints included number of drug-related adverse events, occurrence of hepatotoxicity, cumulative NAC dose, regimen cost, length of hospital and intensive care unit stays, and in-hospital mortality. RESULTS: There were 83 patients identified as meeting the pre-specified inclusion and exclusion criteria. A capped NAC dosing scheme resulted in no difference in hepatic injury when compared to a non-capped regimen (49.4% vs 50%, p = 1.000). The capped dosage regimen was associated with a lower cumulative dose (285.2 mg/kg vs 304.6 mg/kg, p < 0.001) and cost. No other statistically significant differences were identified among the secondary endpoints. CONCLUSION: A capped NAC dosing scheme was not associated with higher rates of hepatic injury or hepatotoxicity in obese patients in the setting of acetaminophen poisoning when compared to a non-capped regimen. Further research is needed to verify these results.
- Published
- 2021
11. Pathophysiology and Treatment of Malignant Hyperthermia
- Author
-
Haili Gregory and Kyle A. Weant
- Subjects
Tachycardia ,Hyperthermia ,Hyperkalemia ,Emergency Nursing ,Tachypnea ,Dantrolene ,Diagnosis, Differential ,03 medical and health sciences ,0302 clinical medicine ,Risk Factors ,medicine ,Humans ,030212 general & internal medicine ,Acidosis ,Muscle Relaxants, Central ,business.industry ,Malignant hyperthermia ,030208 emergency & critical care medicine ,medicine.disease ,Anesthesia ,Emergency Medicine ,medicine.symptom ,Emergency Service, Hospital ,Malignant Hyperthermia ,business ,Rhabdomyolysis ,medicine.drug - Abstract
Malignant hyperthermia (MH) is caused by a genetic disorder of the skeletal muscle that induces a hypermetabolic response when patients are exposed to a triggering agent such as volatile inhaled anesthetics or depolarizing neuromuscular blockers. Symptoms of MH include increased carbon dioxide production, hyperthermia, muscle rigidity, tachypnea, tachycardia, acidosis, hyperkalemia, and rhabdomyolysis. Common scenarios for triggering agents are those used are during surgery and rapid sequence intubation. Hypermetabolic symptoms have a rapid onset; hence, prompt recognition and treatment are vital to prevent morbidity and mortality. The first-line treatment agent for an MH response is dantrolene. Further treatment includes managing complications related to a hypermetabolic response such as hyperkalemia and arrhythmias. This review is focused on the recognition and treatment considerations of MH in the emergency department to optimize therapy and improve patient morbidity and mortality.
- Published
- 2021
12. Latex Allergy Alerts in the Age of CPOE: Assessing the Risk From Injectable Medications
- Author
-
Cynthia M. Phillips, Kyle A. Weant, and Erik A. Preheim
- Subjects
Pharmacology ,medicine.medical_specialty ,Latex allergy ,business.industry ,medicine ,Pharmacology (medical) ,Pharmacy ,Intensive care medicine ,medicine.disease ,business - Published
- 2021
13. Characterization of Emergency Department Rabies Post-Exposure Prophylaxis Procedures with an Infectious Diseases Clinic Referral Process
- Author
-
Alexandra K. Monroe, Kyle A. Weant, Gregory A. Hall, and Jessica J. Frederickson
- Subjects
Pharmacology ,medicine.medical_specialty ,business.industry ,medicine.medical_treatment ,030231 tropical medicine ,Original Articles ,Pharmacy ,Emergency department ,medicine.disease ,Vaccination ,03 medical and health sciences ,0302 clinical medicine ,Clinic referral ,Emergency medicine ,medicine ,Pharmacology (medical) ,Rabies ,030212 general & internal medicine ,Post-exposure prophylaxis ,business - Abstract
Purpose: Rabies post-exposure prophylaxis (rPEP) in the emergency department (ED) is associated with high costs, complicated administration protocols, and a time-sensitive vaccination series that often requires ED follow-up visits for subsequent vaccine administration. This study sought to characterize the number of redirected vaccine administrations in those patients referred to ID Clinic, guideline compliance, and opportunities for improvement. Methods: Retrospective chart review of adult and pediatric patients presenting to the ED from 2016 to 2019 and prescribed rabies immunoglobulin. Results: Of the 89 patients included, 66.3% were referred to ID Clinic. Those referred to clinic had significantly fewer average visits to the ED for repeat vaccination ( P
- Published
- 2020
14. Review of Hematological and Oncological Emergencies
- Author
-
Stephanie Barré, Jessica McElwee, Chara Calhoun, Kyle A. Weant, Andy Maldonado, and Carolyn M. Bell
- Subjects
Neoplasms ,T-Lymphocytes ,Emergency Medicine ,Receptors, Antigen, T-Cell ,Humans ,Emergency Nursing ,Emergencies ,Immunotherapy, Adoptive ,Febrile Neutropenia - Abstract
Patients with hematological malignancies, both treated and untreated, or solid tumors undergoing treatment are at risk of life-threatening complications, which may present in the emergency department (ED). Such emergencies are diverse in etiology and often require prompt treatment. Traditional complications, such as febrile neutropenia, have had recent guideline updates, which incorporate new evidence and a new validated risk stratification tool. In addition, newer approaches to treatment, such as chimeric antigen receptor (CAR) T-cell therapy, are becoming more widely available and have unique associated toxicities. This review discusses the management of the following hematological and oncological emergencies likely to be encountered in the ED: febrile neutropenia, CAR T-cell toxicities, differentiation syndrome, tumor lysis syndrome, hypercalcemia of malignancy, and hyponatremia.
- Published
- 2022
15. Evaluation of burnout among emergency medicine pharmacists
- Author
-
Elizabeth Rozycki, Craig Cocchio, Giles W. Slocum, Nicole M. Acquisto, Mary Beth Shirk, Patrick J. Bridgeman, Matthew H Bilhimer, Meghan Groth, Marc G. Sturgill, Junan Li, and Kyle A. Weant
- Subjects
business.industry ,Pharmacist ,Pharmaceutical Science ,Medicine ,Pharmacology (medical) ,Pharmacy ,Medical emergency ,Burnout ,business ,medicine.disease - Published
- 2020
16. Incidence of anticoagulation medication prescribing errors in patients discharged from the emergency department
- Author
-
Morgan Cantley, Andrew J. Matuskowitz, Kyle A. Weant, Haili Gregory, and Gregory A. Hall
- Subjects
medicine.medical_specialty ,Medication.prescribing ,business.industry ,Incidence (epidemiology) ,Emergency medicine ,Pharmaceutical Science ,Medicine ,Pharmacology (medical) ,Pharmacy ,In patient ,Emergency department ,business - Published
- 2020
17. Emergency Department Management of Recent-Onset Atrial Fibrillation
- Author
-
Haili Gregory, Jeffrey Caporossi, Kyle A. Weant, Gregory A. Hall, and Andrew J. Matuskowitz
- Subjects
medicine.medical_specialty ,Electric Countershock ,MEDLINE ,Emergency Nursing ,Electrocardiography ,03 medical and health sciences ,0302 clinical medicine ,Atrial Fibrillation ,Health care ,medicine ,Humans ,030212 general & internal medicine ,Recent onset ,business.industry ,Anticoagulants ,030208 emergency & critical care medicine ,Atrial fibrillation ,Admission rate ,Medication administration ,Emergency department ,Calcium Channel Blockers ,medicine.disease ,Emergency medicine ,Emergency Medicine ,Pharmacological cardioversion ,Emergency Service, Hospital ,business ,Anti-Arrhythmia Agents ,Sodium Channel Blockers - Abstract
Atrial fibrillation (AF) is the most common tachyarrhythmia managed in the emergency department (ED). Visits to the ED for a presentation of AF have been increasing in recent years, with an admission rate that exceeds 60% in the United States and contributes substantially to health care costs. Recent-onset AF-defined as symptom onset less than 48 hr-is a common ED presentation for which rate control or acute electrical or pharmacological cardioversion may be appropriate treatment modalities depending on patient-specific circumstances. The focus of this review is to discuss the current recommendations regarding the management of recent-onset nonvalvular AF in the ED, discuss medication administration considerations, and identify implementation strategies in the ED to optimize throughput and reduce hospital admissions.
- Published
- 2020
18. A cross‐sectional survey of U.S. hospital pharmacy leaders on departmental initiatives to address burnout
- Author
-
Patrick J. Bridgeman, Nicole M. Acquisto, Giles W. Slocum, Matt Bilhimer, Meghan Groth, Craig Cocchio, Elizabeth Rozycki, Marc Sturgill, and Kyle A. Weant
- Subjects
medicine.medical_specialty ,Cross-sectional study ,Family medicine ,medicine ,Pharmaceutical Science ,Pharmacology (medical) ,Pharmacy ,Hospital pharmacy ,Burnout ,Psychology - Published
- 2020
19. Online Participation in a Pharmacy Residency Research Certificate Program
- Author
-
Erin R. Weeda, Hana Al Alshaykh, Jalaina Brown, and Kyle A. Weant
- Subjects
Pharmacology ,Medical education ,Online participation ,business.industry ,Medicine ,Pharmacology (medical) ,Pharmacy ,business ,Letters to the Editor ,Certificate program - Published
- 2021
20. The Influence of Age on Propofol Dosing Requirements During Procedural Sedation in the Emergency Department
- Author
-
Ryan M Barnes, Maegan E Wells, Jeffrey Caporossi, and Kyle A. Weant
- Subjects
business.industry ,Sedation ,Incidence (epidemiology) ,Incidence ,Conscious Sedation ,Retrospective cohort study ,Emergency department ,Emergency Nursing ,Opioid ,Anesthesia ,Emergency Medicine ,medicine ,Humans ,Hypnotics and Sedatives ,Dosing ,medicine.symptom ,Propofol ,business ,Adverse effect ,Emergency Service, Hospital ,medicine.drug ,Aged ,Retrospective Studies - Abstract
Propofol is a frequently used agent for procedural sedation in the emergency department (ED). Some have suggested that propofol dosing in this setting should be adjusted in elderly patients; however, limited data exist supporting this recommendation. Additional factors that may contribute to altered propofol dose requirements in this setting have not been thoroughly explored. The objective of this analysis was to ascertain the effect age may have on the propofol dose required during procedural sedation in the ED. This retrospective study was conducted at a Level 1 academic medical center ED and included patients 18 years or older who received propofol for procedural sedation from 2015 to 2017. Those patients who were 18-64 years of age were compared with those 65 years or older. Between the two groups, total and weight-based propofol requirements for sedation, opioid doses, and adverse events were compared. This analysis included 101 procedural sedations. The median induction dose and opioid requirements before or during the procedure were not significantly different between the two groups. Compared with patients 18-64 years of age, those 65 years or older had significantly less total weight-based propofol requirements (p = 0.024) and required less total propofol for sedation (p = 0.007). In addition, patients 65 years or older required fewer repeat doses of propofol during the procedure than younger patients (p = 0.043). The incidence of adverse effects, including respiratory suppression, was not significantly different between the two groups. Patients 65 years or older may have lower weight-based propofol dosing requirements than younger patients. Utilizing a reduced total dose and repeat dosing strategy for propofol in this setting may be indicated. Further investigations are recommended to clarify factors that signal the need for more tailored dosing.
- Published
- 2021
21. Implementation of a Procainamide-Based Cardioversion Strategy for the Management of Recent-Onset Atrial Fibrillation
- Author
-
Jeffrey Caporossi, Haili Gregory, Chara Calhoun, Andrew J. Matuskowitz, Michael E. Field, Brent J. Bushkar, Gregory A. Hall, and Kyle A. Weant
- Subjects
Male ,medicine.medical_treatment ,Emergency Nursing ,Procainamide ,Cardioversion ,Atrial Fibrillation ,medicine ,Humans ,In patient ,Recent onset ,Adverse effect ,Infusions, Intravenous ,Stroke ,Retrospective Studies ,business.industry ,Significant difference ,Atrial fibrillation ,Middle Aged ,medicine.disease ,Anesthesia ,Emergency Medicine ,Female ,business ,Emergency Service, Hospital ,Anti-Arrhythmia Agents ,medicine.drug - Abstract
Atrial fibrillation/flutter (AF) remains the most common rhythm disturbance in adult patients presenting to emergency departments (EDs). Although pharmacologic cardioversion has been established as safe and effective in recent-onset AF, its use in U.S. EDs is uncommon. The purpose of this study was to assess the safety and efficacy of intravenous (IV) procainamide for pharmacologic cardioversion in patients presenting to the ED with AF of
- Published
- 2021
22. Characterization of Prophylactic Antimicrobial Therapy Practices for Patients With Marine-Associated Injuries in the Emergency Department
- Author
-
Gregory A. Hall, Lacey MenkinSmith, Kyle A. Weant, Britany N. Byrkit, and Elizabeth C. LaScala
- Subjects
0303 health sciences ,medicine.medical_specialty ,030306 microbiology ,medicine.drug_class ,business.industry ,Antibiotics ,Emergency department ,Antimicrobial ,Disease control ,03 medical and health sciences ,0302 clinical medicine ,Emergency medicine ,Vibrio species ,medicine ,Pharmacology (medical) ,030212 general & internal medicine ,business - Abstract
Background: Centers for Disease Control and Prevention (CDC) recommendations for the treatment of marine-associated wound infections include empiric coverage for Vibrio species with a combination of a third-generation cephalosporin and doxycycline. These recommendations are based on limited data and it remains unclear if this regimen is also indicated for prophylaxis. Objective: The purpose of this analysis was to assess the antibiotic regimens used in the emergency department (ED) for prophylaxis of marine-associated injuries relative to the CDC recommendations and evaluate any clinical impact. Methods: A retrospective review evaluated adult patients discharged from the ED over a 4-year period with an antibiotic prescription following an injury with marine exposure. Results: 114 patients were included in the analysis. The majority of patients were < 40 years of age with no previous medical history and presented after sustaining a laceration secondary to oyster shells. 97.4% received prophylactic antibiotic therapy that did not match the CDC recommendations, with the majority receiving doxycycline monotherapy (82%). A 1.8% 30-day ED revisit rate was noted with 2 patients returning for therapy failure. No patients were admitted to the hospital within 30 days and no documented adverse effects related to antibiotic therapy were noted. Conclusion: Current prophylactic antibiotic prescribing practices diverge from the current CDC recommendations for the treatment of marine-associated infections, however, an effect secondary to these variations was not observed. Further investigations of prophylaxis against Vibrio infections in low-risk patients is warranted to limit collateral damage and improve antimicrobial stewardship in the ED.
- Published
- 2021
23. Advice Provided by a Pharmacy Residency Research Committee
- Author
-
Erin R. Weeda, Rory J. Thomas, Kyle A. Weant, Jean M. Nappi, Eleni A. Gaspar, and Genevieve L. Hayes
- Subjects
Medical education ,business.industry ,Pharmacy Residencies ,Internship and Residency ,Pharmacy ,Education, Pharmacy, Graduate ,Pharmacists ,Advice (programming) ,Students, Pharmacy ,Surveys and Questionnaires ,Medicine ,Humans ,Pharmacology (medical) ,business - Published
- 2021
24. The Cents of the Dosage Cap in Patients Greater than 100 Kilograms Receiving N-Acetylcysteine for Acetaminophen Toxicity
- Author
-
Regan A. Baum, Mark K. Su, and Kyle A. Weant
- Subjects
Drug-Related Side Effects and Adverse Reactions ,Health, Toxicology and Mutagenesis ,The Poison Pen ,Humans ,Analgesics, Non-Narcotic ,Toxicology ,Acetaminophen ,Acetylcysteine - Published
- 2022
25. Feasibility of pharmacists to contribute to multicenter emergency medicine research
- Author
-
Asad E. Patanwala, Kyle A. Weant, and Nicole M. Acquisto
- Subjects
medicine.medical_specialty ,Pharmacotherapy ,business.industry ,Emergency medicine ,Pharmaceutical Science ,Medicine ,Pharmacology (medical) ,Pharmacy ,business - Published
- 2019
26. Safety, efficacy, and cost of four-factor prothrombin complex concentrate (4F-PCC) in patients with factor Xa inhibitor-related bleeding: a retrospective study
- Author
-
Melanie Smith, Lindsay Deloney, Cassandra Carter, Evert A. Eriksson, and Kyle A. Weant
- Subjects
medicine.medical_specialty ,Rivaroxaban ,medicine.drug_mechanism_of_action ,business.industry ,Factor Xa Inhibitor ,Retrospective cohort study ,Hematology ,030204 cardiovascular system & hematology ,medicine.disease ,Prothrombin complex concentrate ,Pericardial effusion ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,Hemostasis ,medicine ,Apixaban ,030212 general & internal medicine ,Cardiology and Cardiovascular Medicine ,business ,Andexanet alfa ,medicine.drug - Abstract
Oral factor Xa (fXa) inhibitor-related bleeding is a concerning drug safety problem. There is considerable controversy surrounding available reversal strategies. The recently approved reversal agent andexanet alfa has limited data, an unclear safety profile, and imparts a substantial financial burden. This has led to the off-label use of four-factor prothrombin complex concentrates (4F-PCC) for this indication. This study aimed to assess the safety and efficacy of 4F-PCC for the management of major bleeding related to oral fXa inhibitors. This observational, retrospective study included adult patients admitted from 2014 to 2018 who received 4F-PCC (Kcentra®) for fXa inhibitor-related major bleeding. Efficacy was assessed using criteria described by Sarode et al. Secondary outcomes included the incidence of thromboembolism, mortality, and a cost analysis comparing 4F-PCC to andexanet alfa for reversal of oral fXa inhibitors. Thirty-one patients received 4F-PCC for major bleeding associated with apixaban (55%) or rivaroxaban (45%). Intracranial hemorrhage (58%) and pericardial effusion (16%) accounted for the majority of bleeding events. Most patients received a single weight-based 4F-PCC dose of 25 units/kg (38.7%) or 50 units/kg (51.6%). Effective hemostasis was achieved in 80.6% of patients. Five patients (16%) died due to acute bleeding and no thromboembolic events were observed. Administration of 4F-PCC was effective for most patients requiring emergent reversal of anticoagulation with apixaban or rivaroxaban and was associated with a low risk of thromboembolic events. Considerable cost differences limit the use of andexanet alfa and may warrant further study of 4F-PCC for fXa inhibitor reversal.
- Published
- 2019
27. Assessment of dose capping in phenytoin loading practices in the emergency department and the impact of an emergency medicine pharmacist
- Author
-
Regan A. Baum, Stephanie Baker Justice, Abby M. Bailey, Martina Holder, and Kyle A. Weant
- Subjects
Phenytoin ,medicine.medical_specialty ,business.industry ,Emergency medicine ,Pharmacist ,Pharmaceutical Science ,Medicine ,Pharmacology (medical) ,Pharmacy ,Emergency department ,business ,medicine.drug - Published
- 2019
28. Implications of the presence of an emergency medicine pharmacist during critical care trauma patient resuscitation
- Author
-
Savannah Lindsey, Christina Pinkston, Kyle A. Weant, Hugh Shoff, and Lynn Lamkin
- Subjects
medicine.medical_specialty ,Resuscitation ,Trauma patient ,business.industry ,Emergency medicine ,medicine ,Pharmacist ,Pharmaceutical Science ,Pharmacology (medical) ,Pharmacy ,business - Published
- 2019
29. Development of a Pharmacy Residency Research Certificate Program
- Author
-
Kyle A. Weant and Erin R. Weeda
- Subjects
Pharmacology ,Medical education ,business.industry ,Pharmacy education ,Pharmacy ,Original Articles ,Certificate ,Certificate program ,Teaching skills ,Medicine ,Pharmacology (medical) ,business ,Pharmacy Residencies - Abstract
Background: Similar to teaching certificate programs, which have been incorporated in many pharmacy residencies to improve teaching skills, resident research certificate programs could provide residents with more exposure to biostatistics and research design. However, few research certificate programs have been described. Objective: To assess the impact of a research certificate program on residents’ attitude toward, confidence in, and knowledge of research. Methods: A resident research certificate program was created for the 2018-2019 residency class at our institution, which included 33 pharmacy residents (15 postgraduate year-1 [PGY1] and 18 PGY2 residents). The program consisted of 7 sessions aimed at providing residents with research training. To earn a certificate, participants were required to attend 6 or more sessions and achieve a score greater than or equal to 70% on a postassessment. An optional questionnaire assessing attitude, confidence, and knowledge was also administered at baseline and following the certificate program. Results: Of the 33 residents participating in the research certificate program, 21 (9 PGY1 and 12 PGY2) residents completed both the baseline and follow-up questionnaire and were included in the analysis. All items assessing attitude and 3 of 6 items assessing confidence improved significantly following the certificate program when compared to baseline ( P < .05 for all). Median knowledge scores were no different on the baseline versus follow-up questionnaire ( P = .54). Conclusions: After completing a research certificate program, resident knowledge scores did not differ from baseline, but attitudes toward research and confidence appeared to improve. Research certificate programs could be an avenue for providing pharmacy residents with increased exposure to and comfort with biostatistics and research design.
- Published
- 2021
30. A Case Report of Hypoglycemia Following a Tramadol Overdose in a Non-Diabetic Patient
- Author
-
Alexander M. Clendening, Jeffrey S. Bush, and Kyle A. Weant
- Subjects
Blood Glucose ,Male ,030204 cardiovascular system & hematology ,Pharmacology ,Hypoglycemia ,Norepinephrine (medication) ,03 medical and health sciences ,0302 clinical medicine ,medicine ,Humans ,Pharmacology (medical) ,030212 general & internal medicine ,Receptor ,Tramadol ,Acetaminophen ,business.industry ,Middle Aged ,medicine.disease ,Analgesics, Opioid ,Serotonin ,Drug Overdose ,Opioid analgesics ,business ,Non diabetic ,medicine.drug - Abstract
Introduction: Tramadol is an opioid analgesic that binds to mu-opioid receptors and inhibits the uptake of norepinephrine and serotonin. Through its activation of these receptors, it has potential to increase the utilization of glucose and/or decrease hepatic gluconeogenesis. Case Report: A 55-year-old male presents to the Emergency Department (ED) via Emergency Medical Services (EMS) following a self-reported overdose of alprazolam, lorazepam, acetaminophen with codeine, and tramadol. During EMS transport, the patient was found to be hypoglycemic with a glucose of 30 mg/dL and was administered 25 grams of intravenous (IV) dextrose 50% in water. The patient had no past medical history of diabetes mellitus, hypoglycemia, or hyperglycemia and was normoglycemic on his prior presentations to our facility 3 months and 2 years prior. Subsequent analysis found that the patient was negative for acetaminophen, ethanol, salicylates, tricyclics, and lithium. His urinalysis was positive for opiates and benzodiazepines. Upon arrival to the ED, the patient’s blood glucose was 131 mg/dL but subsequently dropped to 73 mg/dL, necessitating the initiation of continuous IV fluids containing dextrose. These fluids were discontinued 3.5 hrs later and the patient was discharged 16 days later. Discussion: This case illustrates that hypoglycemia can be a presenting symptom in patients with an acute overdose of tramadol with no previous history of glycemic dysregulation. Upon presentation it is important to closely monitor serum glucose concentrations to identify hypoglycemia early in order to initiate necessary hypoglycemia protocols.
- Published
- 2021
31. Efficacy of bolus-dose epinephrine to manage hypotension in the prehospital setting
- Author
-
Kyle A. Weant and David M. French
- Subjects
Male ,Emergency Medical Services ,Epinephrine ,business.industry ,Incidence (epidemiology) ,General Medicine ,Emergency department ,Middle Aged ,Multiple dosing ,Primary outcome ,Blood pressure ,Anesthesia ,Heart rate ,Emergency Medicine ,medicine ,Humans ,Individual dose ,Female ,Hypotension ,Sympathomimetics ,business ,medicine.drug ,Retrospective Studies - Abstract
Hypotension in the Emergency Department (ED) and the prehospital setting has been associated with significant morbidity and mortality. Limited literature exists exploring the utilization of intravenous (IV) bolus-dose epinephrine (BDE) by Emergency Medical Services (EMS).A retrospective review evaluated patients transported to an academic medical center who had received IV BDE by a single urban EMS system from 2016 to 2020. The primary outcome was to assess the influence IV BDE had on systolic blood pressure (SBP). Secondary objectives were to assess changes in heart rate (HR), the impact of dose variability on SBP, and the incidence of severe hypertension (SBP220 mmHg).A total of 55 patients who received 96 administrations of IV BDE were included in the analysis. The most common individual dose was 10 μg (76.0%) and 45.5% received multiple doses. The median weight-based dose of BDE was 0.14 μg/kg. A significant increase in SBP (median 14.0 mmHg) was noted among all patients following BDE administration compared with baseline (p0.001). No significant difference was found in HR following BDE compared with baseline (p = 0.375). Those that received a BDE dose10 μg were noted to have a significantly greater rise in SBP than those that received 10 μg (30.0 mmHg vs. 11.0 mmHg; p = 0.022). Similarly, patients that received a dose ≥0.2 μg/kg had a significantly greater increase in SBP compared with those that received0.2 μg/kg (30.0 mmHg vs. 10.0 mmHg; p = 0.048). There were no incidences of severe hypertension following therapy.The utilization of IV BDE in the prehospital setting for acute hypotension resulted in a significant rise in SBP. A dose-response relationship was noted both in terms of a flat-based dose and a weight-based dose, with higher doses yielding a greater change in SBP. Additional investigations are necessary to further explore the most appropriate dose of this agent in this setting and its influence, if any, on clinical outcomes.
- Published
- 2021
32. Key articles and guidelines for the emergency medicine clinical pharmacist: 2011-2018 update
- Author
-
Giles W. Slocum, Asad E. Patanwala, Gary D. Peksa, Stephanie Baker Justice, Michael C. Thomas, Nadia I. Awad, Gregory Kelly, Blake A. Porter, Matthew H Bilhimer, Nicole M. Acquisto, Donna M Shuler Truoccolo, Cierra N Treu, Kyle A. Weant, and Therese Makhoul
- Subjects
medicine.medical_specialty ,Pharmacist ,Pharmacy ,030204 cardiovascular system & hematology ,Pharmacists ,03 medical and health sciences ,Patient safety ,0302 clinical medicine ,Professional Role ,Medicine ,Humans ,030212 general & internal medicine ,Pharmacology ,Evidence-Based Medicine ,Emergency management ,business.industry ,Health Policy ,Evidence-based medicine ,Emergency department ,Clinical pharmacy ,Emergency medicine ,Practice Guidelines as Topic ,Emergency Medicine ,business ,Emergency Service, Hospital ,Pharmacy Service, Hospital ,Respiratory care - Abstract
Purpose To summarize recently published research reports and practice guidelines on emergency medicine (EM)–related pharmacotherapy. Summary Our author group was composed of 14 EM pharmacists, who used a systematic process to determine main sections and topics for the update as well as pertinent literature for inclusion. Main sections and topics were determined using a modified Delphi method, author and peer reviewer groups were formed, and articles were selected based on a comprehensive literature review and several criteria for each author-reviewer pair. These criteria included the document “Oxford Centre for Evidence-based Medicine – Levels of Evidence (March 2009)” but also clinical implications, interest to reader, and belief that a publication was a “key article” for the practicing EM pharmacist. A total of 105 articles published from January 2011 through July 2018 were objectively selected for inclusion in this review. This was not intended as a complete representation of all available pertinent literature. The reviewed publications address the management of a wide variety of disease states and topic areas that are commonly found in the emergency department: analgesia and sedation, anticoagulation, cardiovascular emergencies, emergency preparedness, endocrine emergencies, infectious diseases, neurology, pharmacy services and patient safety, respiratory care, shock, substance abuse, toxicology, and trauma. Conclusion There are many important recent additions to the EM-related pharmacotherapy literature. As is evident with the surge of new studies, guidelines, and reviews in recent years, it is vital for the EM pharmacist to continue to stay current with advancing practice changes.
- Published
- 2020
33. Incidence of prescription errors in patients discharged from the emergency department
- Author
-
Andrew J. Matuskowitz, Kyle A. Weant, Gregory A. Hall, Morgan Cantley, Chara Calhoun, and Haili Gregory
- Subjects
High rate ,medicine.medical_specialty ,business.industry ,Incidence (epidemiology) ,Incidence ,030208 emergency & critical care medicine ,General Medicine ,Emergency department ,Drug Prescriptions ,Patient Discharge ,03 medical and health sciences ,0302 clinical medicine ,Emergency medicine ,Emergency Medicine ,medicine ,Humans ,Medication Errors ,In patient ,Continuity of care ,Medical prescription ,business ,Emergency Service, Hospital ,Retrospective Studies - Abstract
The Emergency Department (ED) is known for its high rates of medication errors secondary to many characteristics such as unfamiliar patients, lack of continuity of care, increasing patient volumes, reliance on verbal orders, and fewer safety mechanisms. The purpose of this study was to quantify and characterize the medication errors that occur in patients discharged from the ED.Prescriptions for patients discharged from the adult ED at an academic medical center from 2015 to 2018 were reviewed. Errors in discharge medication orders were documented as well as characteristics of these errors including medication class, errors in prescription directions, quantity prescribed, and refills given inappropriately.A total of 115,933 prescriptions were reviewed and a total of 20,498 errors were identified within 19,126 prescriptions. Of the errors identified, 4048 (19.7%) involved prescription directions, 6537 (31.9%) were errors in quantity prescribed, and 9913 (48.4%) were prescriptions written with refills. The proportion of errors among different prescriber statuses was significantly different when comparing all prescribers (p .001). Prescriptions written by Non-Emergency Medicine residents had significantly more errors in quantity and refills (p .001, p .001), and prescriptions written by Emergency Medicine residents had significantly more errors in directions (p .001).This review identified a 16.5% error rate among all prescriptions provided to patients upon ED discharge that varied among different subcategories of medications. This is consistent with the limited literature that is currently available on the topic. These results could assist institutions in developing targeted mitigation strategies to limit medication misadventures in patients discharged from the ED.
- Published
- 2020
34. Impact of an Advanced Pharmacy Practice Experience Student-Run 'Meds 2 Beds' and Discharge Counseling Program on Quality of Care
- Author
-
Jessie Morgan, Jennifer Wiedmar, Brette Conliffe, Kyle A. Weant, Vanessa VanArsdale, and Jocelyn VanOpdorp
- Subjects
Pharmacology ,medicine.medical_specialty ,business.industry ,Original Articles ,Pharmacy ,Emergency department ,Pay for performance ,030226 pharmacology & pharmacy ,03 medical and health sciences ,0302 clinical medicine ,Patient satisfaction ,Family medicine ,Health care ,medicine ,Pharmacology (medical) ,Pharmacy practice ,030212 general & internal medicine ,Outcomes research ,Medical prescription ,business ,Reimbursement - Abstract
Purpose: As health care progresses toward pay for performance reimbursement models and focus is placed on the patient as a consumer, health care systems must adapt by initiating new programs and services. This institution responded by implementing a “Meds 2 Beds” program integrating clinical services with dispensing and medication delivery during transitions of care. This study evaluates outcomes relevant to patients, health care providers, pharmacists, and administrators. Methods: This observational chart review evaluated the effectiveness of a “Meds 2 Beds” program from May 1, 2014, through December 1, 2015. Patients who participated in this program were matched 1:1 with controls who did not. The primary outcome was 30-day hospital readmission. Secondary outcomes included 30-day emergency department (ED) visits, patient satisfaction, and financial impact. Results: In this sample, 185 “Meds 2 Beds” patients were matched to 185 controls. Thirty day readmission occurred in 16 (8.7%) “Meds 2 Beds” cases and 19 (10.3%) controls ( P = .71). Rates of 30-day ED visits were nonsignificantly reduced in cases (22 [11.9%] vs 33 [18.1%]; odds ratio = 0.62, P = .11) and occurred significantly later (11 vs 7 days, P = .03). Conclusions: This study showcases a creative medication delivery and discharge counseling program. The program provides financial benefit to the institution creating a direct revenue stream from prescription dispensing while highlighting a potential for reduced readmissions and ED visits (although a statistically significant difference was not demonstrated in this analysis). A similar model can be adopted by other health care institutions to improve the quality of patient care.
- Published
- 2018
35. A Comparison of 10% Dextrose and 50% Dextrose for the Treatment of Hypoglycemia in the Prehospital Setting
- Author
-
Daniel Combs, Lindsay Deloney, Grace Elsey, Kyle A. Weant, and David M. French
- Subjects
medicine.medical_specialty ,Emergency Medical Services ,business.industry ,030208 emergency & critical care medicine ,030209 endocrinology & metabolism ,Hypoglycemia ,medicine.disease ,Hospitalization ,03 medical and health sciences ,0302 clinical medicine ,Glucose ,Emergency medicine ,medicine ,Emergency medical services ,Humans ,Pharmacology (medical) ,Limited evidence ,business ,Retrospective Studies - Abstract
Background: Hypoglycemia is a frequent cause of emergency medical services (EMS) activation; however, limited evidence exists to support optimal prehospital treatment. Objective: This study sought to compare the safety and efficacy of the administration of 10% dextrose (D10) intravenously (IV) versus 50% dextrose (D50) IV for the treatment of hypoglycemia in the prehospital setting. Methods: This was a retrospective cohort study of patients who received IV dextrose by EMS and were transported to an academic teaching hospital emergency department between 2014 and 2017. Results: Four hundred seventy-eight eligible patients were reviewed, with 161 patients receiving D10 and 150 patients receiving D50. There was no significant difference found regarding the need for dextrose retreatment prior to hospital arrival between the D10 and D50 groups (0.6% vs 2.0%; P = .565). The prehospital reassessment glucose in the D50 group was a significantly higher than the D10 group (151.9 vs 124.6 mg/dL, P = .001) and this difference was maintained on hospital arrival (129.5 vs 108.0 mg/dL, P = .011). No significant difference was found between groups with regard to hospital admission, length of stay, or in-hospital mortality. Conclusion: When comparing D10 with D50 for the treatment of hypoglycemia by EMS, there were no significant differences in the need for dextrose retreatment prior to hospital arrival. The use of D50 resulted in a significantly higher blood glucose concentrations both in the prehospital setting and upon hospital arrival. Further study is needed in larger patient populations to evaluate the use of D10, the need for dextrose readministration, and its impact on clinical outcomes.
- Published
- 2019
36. Modified two step N-acetylcysteine dosing regimen for the treatment of acetaminophen overdose a safe alternative
- Author
-
Regan A. Baum, Abby M. Bailey, Adam Dugan, Elise L. Metts, Scott Wilkie, and Kyle A. Weant
- Subjects
Acetylcysteine ,Regimen ,acetaminophen overdose ,business.industry ,Anesthesia ,digestive, oral, and skin physiology ,Two step ,Dosing regimen ,medicine ,business ,medicine.drug ,Acetaminophen - Abstract
Intravenous N-acetylcysteine (IV NAC) is currently the approved treatment for acetaminophen (APAP) overdose with a three-step regimen totaling 300 mg/kg over 21 hours. Due to the complexity of this...
- Published
- 2018
37. Antiemetic Use in the Emergency Department
- Author
-
Stephanie Baker Justice, Abby M. Bailey, Chara Calhoun, Kyle A. Weant, and Regan A. Baum
- Subjects
Antiemetic Agent ,medicine.medical_specialty ,Vomiting ,medicine.drug_class ,Nausea ,Emergency Nursing ,03 medical and health sciences ,0302 clinical medicine ,medicine ,Humans ,Antiemetic ,030212 general & internal medicine ,Intensive care medicine ,Prescribed medications ,Medication use ,business.industry ,Emergency department ,Anesthesia ,Emergency Medicine ,Etiology ,Antiemetics ,030211 gastroenterology & hepatology ,medicine.symptom ,Emergency Service, Hospital ,business - Abstract
Nausea and vomiting are 2 of the most common complaints of patients presenting to the emergency department (ED). In addition, antiemetics are the most commonly prescribed medications in the ED behind analgesics. Treating these conditions can be complex, especially as one considers that nausea and/or vomiting could be the primary presenting illness or simply a symptom of a more complex etiology. Although there is a wide variety of pharmacotherapeutic options in the armamentarium to treat these conditions, very few consensus recommendations exist to help guide the use of antiemetic agents in the ED, leading to wide variability in medication use. Contributing to these variations in practice is the extended spectrum of etiologies and potential physiological factors that contribute to the development of nausea or vomiting. A thorough understanding of the pharmacology and administration of these agents can help practitioners devise tailored antiemetic regimens based upon the underlying etiology.
- Published
- 2017
38. Weight-based versus non-weight-based diltiazem dosing in the setting of atrial fibrillation with rapid ventricular response
- Author
-
Erin R. Weeda, Jeffrey Caporossi, Chara Calhoun, Jennifer L. Radke, Andrew J. Matuskowitz, Kyle A. Weant, Gregory A. Hall, and Sara M. Ward
- Subjects
medicine.medical_specialty ,Management of atrial fibrillation ,03 medical and health sciences ,Diltiazem ,0302 clinical medicine ,Heart Rate ,Internal medicine ,Atrial Fibrillation ,medicine ,Humans ,Dosing ,Adverse effect ,Aged ,Retrospective Studies ,Dose-Response Relationship, Drug ,business.industry ,Body Weight ,030208 emergency & critical care medicine ,Atrial fibrillation ,General Medicine ,Emergency department ,Middle Aged ,medicine.disease ,Calcium Channel Blockers ,Rapid ventricular response ,Case-Control Studies ,Emergency Medicine ,Cardiology ,Administration, Intravenous ,business ,Weight based dosing ,medicine.drug - Abstract
There is conflicting evidence to support the superiority of weight-based (WB) dosing of intravenous (IV) diltiazem over non-weight-based (NWB) dosing strategies in the management of atrial fibrillation (AFib) with rapid ventricular response (RVR).A retrospective review evaluated patients presenting to the emergency department (ED) in AFib with RVR and receiving IV diltiazem from 2015 to 2018. Those receiving a NWB dose were compared with those receiving a WB dose based on actual body weight (ABW). Secondary analyses evaluated safety profiles of the regimens and compared response in groups defined by ABW or ideal body weight (IBW).A total of 371 patients were included in the analysis. No significant difference was observed in achieving a therapeutic response (66.5% vs. 73.1%, p = 0.18) or adverse events between the groups. Patients receiving a WB dose were significantly more likely to have a HR 100 bpm than those receiving a NWB dose (40.9% vs. 53.5%, p = 0.01). When groups were defined by IBW, WB dosing was associated with a significantly higher incidence of achieving a therapeutic response (62.7% vs. 74.3%, p = 0.02).In patients presenting with AF with RVR, there was no significant difference in achieving a therapeutic response between the two strategies. A WB dosing approach did result in a greater proportion of patients with a HR 100 bpm. The utilization of IBW for WB dosing may result in an increased achievement of a therapeutic response.
- Published
- 2019
39. Compliance and Related Outcomes of Prophylactic Antibiotics in Traumatic Open Fractures
- Author
-
Stephanie Baker Justice, Regan A. Baum, Hannah C. Johnson, Kyle A. Weant, and Abby M. Bailey
- Subjects
Pharmacology ,medicine.medical_specialty ,Standard of care ,Prophylactic antibiotic therapy ,medicine.drug_class ,business.industry ,Antibiotics ,030208 emergency & critical care medicine ,Pharmacy ,Original Articles ,Compliance (physiology) ,03 medical and health sciences ,0302 clinical medicine ,medicine ,Pharmacology (medical) ,030212 general & internal medicine ,business ,Intensive care medicine - Abstract
Purpose: Prophylactic antibiotic therapy is a standard of care for patients who present with open fractures due to the risk of infectious complications. This study was conducted to characterize the use of initial prophylactic antibiotic use in open fractures, guideline compliance, and its impact on care. Methods: Retrospective chart review of adult patients presenting with an open fracture to a Level 1 Trauma Center Emergency Department over a 12-month period was conducted. Results: Of the 202 patients meeting inclusion criteria, overall compliance with guideline recommendations for antibiotic prophylaxis was found to be 33.2%. The duration of prophylactic therapy was significantly longer in the noncompliant group and among those who received a secondary antibiotic ( P < .05 for both comparisons). The duration of therapy was found to be significantly longer in those patients who developed an infection ( P < .001). Those who developed an infection had a longer hospital length of stay (LOS) ( P < .001) and intensive care unit LOS ( P = .002). In addition, those who developed an infection had significantly more surgeries ( P < .001) and received more red blood cell transfusions ( P < .001). Correlation analysis confirmed a significant association between infection and duration of antibiotic prophylaxis ( P = .02), number of surgeries ( P < .0001), and number of transfusions ( P < .0001). Conclusion: Guideline compliance was exceedingly low due to the extended duration of initial antibiotic therapy and did not appear to yield any clinical benefits. Infection was significantly associated with longer duration of initial prophylactic therapy and morbidity. Opportunities exist to elevate compliance with guidelines and to reevaluate prophylactic antimicrobial therapy in this setting.
- Published
- 2019
40. Effectiveness of glucagon in relieving esophageal foreign body impaction: a multicenter study
- Author
-
Kyle A. Weant, Ryan P. Bodkin, Stephanie Baker Justice, Matthew T. Spencer, and Nicole M. Acquisto
- Subjects
Adult ,Male ,endocrine system ,Adolescent ,Glucagon ,Young Adult ,03 medical and health sciences ,Esophagus ,0302 clinical medicine ,Gastrointestinal Agents ,Humans ,Medicine ,030212 general & internal medicine ,Child ,Adverse effect ,Aged ,Retrospective Studies ,Aged, 80 and over ,Gastrointestinal agent ,Univariate analysis ,business.industry ,Impaction ,Endoscopy ,Retrospective cohort study ,General Medicine ,Middle Aged ,Foreign Bodies ,Treatment Outcome ,Child, Preschool ,Concomitant ,Anesthesia ,Emergency Medicine ,Vomiting ,Female ,030211 gastroenterology & hepatology ,medicine.symptom ,Emergency Service, Hospital ,business ,hormones, hormone substitutes, and hormone antagonists - Abstract
Purpose Glucagon is thought to decrease lower esophageal sphincter tone and is used as an alternative to invasive endoscopy for esophageal foreign body impaction (EFBI). The purpose of this study was to evaluate efficacy and safety of glucagon and identify characteristics associated with success. Methods A multicenter, retrospective study of patients receiving glucagon for EFBI at 2 academic emergency departments was conducted between 2006 and 2010. A control group of patients that did not receive glucagon was evaluated. Data collection included demographics, type of foreign body, glucagon dose, resolution of impaction, incidence of vomiting, additional medication, and endoscopy required. Descriptive and univariate analysis was performed as appropriate. Results A total of 133 doses of glucagon were administered in 127 patients. Glucagon-related resolution of EFBI occurred in 18 patients (14.2%) and vomiting in 16 patients (12.6%). No statistical differences between successful and unsuccessful groups were seen with the exception of concomitant medication administration (benzodiazepine or nitroglycerin) being associated with less glucagon success, 33.3% vs 59.6%, respectively (P = .04). Eighty-four percent of patients in the unsuccessful group underwent endoscopy. Comparing those that received glucagon (n = 127) and the control group (n = 29), there was no significant difference in resolution of EFBI, 14.2% vs 10.3%, respectively (P = .586). Conclusions Glucagon-related resolution occurred in 14.2% of patients and was not significantly different compared with those that did not receive glucagon (10.3%). Concomitant medication administration was associated with lower success. Overall, glucagon had a low success rate, was related to adverse effects, and does not offer advantages for treatment.
- Published
- 2016
41. Complements Are Not Always a Good Thing
- Author
-
Kyle A. Weant, Abby M. Bailey, Brittany S. Reed, and Stephanie Baker Justice
- Subjects
medicine.medical_specialty ,Epinephrine ,Histamine Antagonists ,Alternative medicine ,MEDLINE ,Complement C1 Inactivator Proteins ,Emergency Nursing ,Plasma ,03 medical and health sciences ,0302 clinical medicine ,Adrenal Cortex Hormones ,medicine ,Humans ,030212 general & internal medicine ,Intensive care medicine ,Past medical history ,Angioedema ,Respiratory distress ,business.industry ,Angioedemas, Hereditary ,Emergency department ,medicine.disease ,Surgery ,030228 respiratory system ,Hereditary angioedema ,Emergency Medicine ,medicine.symptom ,Emergency Service, Hospital ,business ,Anaphylaxis - Abstract
Hereditary angioedema attacks are rare, but emergency care providers must be aware of the clinical presentation and treatment of these patients because the emergency department remains the most common setting where these patients seek treatment. If providers are not aware of the past medical history of these patients, they are likely to receive standard therapies for respiratory distress and anaphylaxis including antihistamines, corticosteroids, and epinephrine. However, these medications may not work in these patients, given the pathophysiology of their underlying disease. Since 2009, several new therapies have been approved for the treatment of acute hereditary angioedema attacks. This article discusses pathophysiology, clinical presentation, and use of novel therapies for the management of angioedema.
- Published
- 2016
42. Implications of Statin Use on Vasopressor Therapy in the Setting of Septic Shock
- Author
-
Kyle A. Weant, Christina Pinkston, Jennifer Wiedmar, and Chelsey M. McPheeters
- Subjects
medicine.medical_specialty ,Statin ,medicine.drug_class ,Population ,Pharmacy ,Sepsis ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,medicine ,Pharmacology (medical) ,In patient ,030212 general & internal medicine ,education ,Pharmacology ,education.field_of_study ,Septic shock ,Critically ill ,business.industry ,Organ dysfunction ,030208 emergency & critical care medicine ,Articles ,Statin treatment ,medicine.disease ,medicine.symptom ,business - Abstract
Background: Pleiotropic anti-inflammatory and immunomodulatory effects of statins have been associated with improved outcomes in the critically ill population. Objective: To evaluate the implications of prior statin use on the duration of vasopressor therapy in the setting of septic shock. Methods: This was a retrospective, multicenter study of adult patients who were diagnosed with septic shock. Patients were included if they were treated with any vasopressor for greater than 6 hours from the time of admission. The primary outcome was to compare the duration of vasopressor therapy in patients with septic shock with and without previous statin exposure. Results: A total of 88 statin-exposed cases and 205 unexposed controls were included in the analysis. Despite 92% of statin-exposed patients being reinitiated on therapy within 24 hours, the duration of vasopressors did not differ between groups (44 hours, statin group vs 53 hours, control group, P = .51). There were also no mortality differences between the statin group and the controls (40% vs 47%, P = .27). Conclusions: Long-term statin exposure does not impact the duration of vasopressor therapy in septic shock. The lack of differences in clinical outcomes supports the concept that sepsis involves pro- and anti-inflammatory pathways as well as other nonimmunologic pathways. Results lend further credence to the recent conceptualization of sepsis, with complications leading to organ dysfunction caused not primarily due to inflammatory responses but by a dysregulated response to infection.
- Published
- 2018
43. Outpatient Treatment of Uncomplicated Urinary Tract Infections in the Emergency Department
- Author
-
Kyle A. Weant, Geoffrey E. Hayden, Simon C Watson, and Douglas Schutz
- Subjects
medicine.medical_specialty ,medicine.drug_class ,business.industry ,Urinary system ,Antibiotics ,Local scale ,MEDLINE ,Antimicrobial susceptibility ,030208 emergency & critical care medicine ,Emergency department ,Emergency Nursing ,Patient care ,Anti-Bacterial Agents ,03 medical and health sciences ,0302 clinical medicine ,Ambulatory care ,Urinary Tract Infections ,Emergency Medicine ,medicine ,Ambulatory Care ,Humans ,030212 general & internal medicine ,Intensive care medicine ,business ,Emergency Service, Hospital - Abstract
One of the most commonly treated infections in the emergency department (ED) is an uncomplicated urinary tract infection. Multiple classes of antibiotics are frequently used to treat this condition, but not all have equivalent efficacy, and many may confer risks to not only the patient but society as a whole if used on a large scale. These antibiotic selections should also be guided by local antimicrobial susceptibility patterns, and general multidisciplinary recommendations for therapy should be developed on a local scale to assist prescribing patterns. The proactive development of a routine approach to reviewing and addressing positive cultures following discharge from the ED should also be developed and implemented in order to ensure that optimal patient care is provided. The objective of this review is to assess the available literature to isolate which antibiotics and approaches to care are the most appropriate options for treating uncomplicated outpatient urinary tract infections in the ED.
- Published
- 2018
44. Impact of Rocuronium and Succinylcholine on Sedation Initiation After Rapid Sequence Intubation
- Author
-
Eric G. Johnson, Alicia Shirakbari, Kyle A. Weant, Alex Meier, and Stephanie Baker Justice
- Subjects
Adult ,Male ,medicine.medical_specialty ,Time Factors ,medicine.drug_class ,Sedation ,medicine.medical_treatment ,Conscious Sedation ,Succinylcholine ,Endotracheal intubation ,Pharmacists ,Young Adult ,Intubation, Intratracheal ,Humans ,Medicine ,Intubation ,Androstanols ,Rocuronium ,Retrospective Studies ,Retrospective review ,business.industry ,Emergency department ,Length of Stay ,Middle Aged ,Respiration, Artificial ,Surgery ,Intensive Care Units ,Anesthesia ,Sedative ,Emergency Medicine ,Female ,Analgesia ,medicine.symptom ,business ,Neuromuscular Nondepolarizing Agents ,medicine.drug - Abstract
Rapid sequence intubation (RSI) involves a rapidly acting sedative plus a neuromuscular blocking agent (NMBA) to facilitate endotracheal intubation. Rocuronium and succinylcholine are NMBAs commonly used in RSI with drastically different durations of action.Evaluate whether patients receiving RSI with a longer-acting NMBA had a greater delay in sedation or analgesia than patients that received a short-acting NMBA.This was a retrospective review of patients presenting to the emergency department requiring endotracheal intubation. Exclusions included age18 years, pregnancy, prior intubation, and contraindication to sedation and analgesia. Primary endpoint was time to continuous sedation or analgesia after RSI in patients receiving rocuronium or succinylcholine. Secondary endpoints included hospital length of stay (HLOS), intensive care unit length of stay (ICU LOS), and impact of an emergency medicine pharmacist (EPh).A total 106 patients met inclusion criteria, 76 patients receiving rocuronium and 30 receiving succinylcholine. Mean time to sedation or analgesia was longer in the rocuronium group when compared to the succinylcholine group at 34 ± 36 min vs. 16 ± 21 min (p = 0.002). In the presence of an EPh, the mean time to sedation or analgesia was 20 ± 21 min, vs. 49 ± 45 min (p0.001). Time spent on ventilator, HLOS, and ICU LOS were not significantly different between groups.Patients receiving rocuronium in RSI had a significantly longer time to sedation or analgesia when compared to patients receiving succinylcholine. The presence of an EPh significantly decreased the time to administration of sedation or analgesia after RSI.
- Published
- 2015
45. Antibiotic Prophylaxis for Open Fractures in the Emergency Department
- Author
-
Abby M. Bailey, Regan A. Baum, Stephanie Baker Justice, and Kyle A. Weant
- Subjects
medicine.medical_specialty ,business.industry ,Emergency medicine ,Emergency Medicine ,Medicine ,Emergency department ,Emergency Nursing ,Antibiotic prophylaxis ,business ,Intensive care medicine - Published
- 2015
46. Update on Sepsis Treatment in the Emergency Department
- Author
-
Kyle A. Weant and Abby M. Bailey
- Subjects
medicine.medical_specialty ,Resuscitation ,business.industry ,MEDLINE ,Guideline ,Emergency department ,030204 cardiovascular system & hematology ,Emergency Nursing ,medicine.disease ,Sepsis ,03 medical and health sciences ,0302 clinical medicine ,Intervention (counseling) ,Emergency medicine ,Emergency Medicine ,medicine ,030212 general & internal medicine ,Intensive care medicine ,business - Abstract
Sepsis continues to be a devastating, costly, and challenging syndrome to manage in emergency departments (ED) across the nation, and its impact seems to be only increasing. Recently, consensus recommendations have made some profound changes in the way we approach, classify, and treat sepsis. The ED serves as an important initial screening and intervention point for sepsis, and ED care can have a profound impact on overall morbidity and mortality. The provision of early fluid resuscitation, antimicrobial therapy, and vasopressor therapy, if appropriate, is essential in early care. The intent of this review was to compare and contrast changes associated with the management of sepsis in the ED, with particular focus on guideline recommendations for pharmacotherapeutic management.
- Published
- 2017
47. Delayed hematologic toxicity following rattlesnake envenomation unresponsive to crotalidae polyvalent antivenom
- Author
-
George A. Davis, Abby M. Bailey, Stephanie Baker Justice, and Kyle A. Weant
- Subjects
Male ,Pediatrics ,medicine.medical_specialty ,Time Factors ,Antivenom ,Snake Bites ,Hemorrhage ,Hematologic toxicity ,030204 cardiovascular system & hematology ,Drug Administration Schedule ,03 medical and health sciences ,Immunoglobulin Fab Fragments ,Young Adult ,0302 clinical medicine ,Recurrence ,Crotalid Venoms ,Coagulopathy ,Medicine ,Crotalidae polyvalent immune fab ,Animals ,Humans ,Envenomation ,Immunoglobulin Fragments ,business.industry ,Antivenins ,Crotalus ,030208 emergency & critical care medicine ,General Medicine ,Blood Coagulation Disorders ,medicine.disease ,Thrombocytopenia ,Surgery ,Treatment Outcome ,Emergency Medicine ,business - Abstract
North American rattlesnake envenomations are known to produce coagulopathies and thrombocytopenia. However, the occurrence of delayed hematologic toxicity (less than seven days after envenomation) is poorly characterized in the medical literature. While the recurrence of hematologic derangements has been documented following envenomation, it is usually in the absence of clinically significant bleeding. Although commonly recommended to treat delayed coagulopathies, the effectiveness of crotalidae polyvalent immune Fab ovine (CroFab®) in managing this condition remains in question and warrants further investigation and exploration. We describe the case of a 19-year-old male who presented following rattlesnake envenomation at a church service who was treated with antivenin for 48 h and discharged home only to return four days later with profound thrombocytopenia, coagulopathy, and clinically significant bleeding.
- Published
- 2017
48. Chemotherapy in the Emergency Department? There Is a Role for That: Methotrexate for Ectopic Pregnancy
- Author
-
Kyle A. Weant, Chara Calhoun, Stephanie Baker Justice, Regan A. Baum, and Abby M. Bailey
- Subjects
Adult ,medicine.medical_specialty ,medicine.medical_treatment ,Emergency Nursing ,03 medical and health sciences ,0302 clinical medicine ,Pharmacotherapy ,Pregnancy ,Medicine ,Humans ,Vaginal bleeding ,030212 general & internal medicine ,Adverse effect ,Chemotherapy ,Abortifacient Agents, Nonsteroidal ,030219 obstetrics & reproductive medicine ,Ectopic pregnancy ,business.industry ,Emergency department ,medicine.disease ,United States ,Surgery ,Pregnancy, Ectopic ,Methotrexate ,Emergency medicine ,Emergency Medicine ,Female ,medicine.symptom ,business ,Emergency Service, Hospital ,medicine.drug - Abstract
Approximately 1.6% of all emergency department (ED) visits in the United States are for vaginal bleeding in early pregnancy, translating to around 500,000 ED visits per year. A potentially life-threatening condition, ectopic pregnancy occurs in 1.5%-2% of pregnancies. Many patients will require either surgical or pharmacological intervention following a positive diagnosis. With regard to pharmacological options, methotrexate, largely known for its use in the oncology arena, has emerged as the most effective nonsurgical option and the pharmacological agent of choice. However, this therapy is not without its own unique adverse event profile and patients should be adequately educated on the monitoring parameters of this pharmacotherapy.
- Published
- 2017
49. Being Prepared
- Author
-
Kyle A, Weant, Abby M, Bailey, Elise L, Fleishaker, and Stephanie B, Justice
- Subjects
Hemorrhagic Fevers, Viral ,Emergency Medicine ,Humans ,Botulism ,Disaster Planning ,Emergency Nursing ,Bioterrorism ,Emergency Treatment ,Smallpox - Abstract
Although several biological agents have been recognized as presenting a significant threat to public health if used in a bioterrorist attack, those that are of greatest importance are known as the Category A agents: Bacillus anthracis (anthrax); variola major (smallpox); Yersinia pestis (plague); Francisella tularensis (tularemia); ribonucleic acid viruses (hemorrhagic fevers); and Clostridium botulinum (botulism toxin). In the previous issue, Part I of this review focused on the clinical presentation and treatment of anthrax, plague, and tularemia. In this second part of this 2-part review of these agents, the focus is on the clinical presentation and treatment of smallpox, viral hemorrhagic fevers, and botulism toxin. The utilization of mass prophylaxis to limit the morbidity and mortality associated with all these agents is also discussed along with the role emergency care personnel play in its implementation.
- Published
- 2014
50. Being Prepared
- Author
-
Kyle A. Weant, Elise L. Fleishaker, Abby M. Bailey, and Stephanie Baker Justice
- Subjects
medicine.medical_specialty ,Education, Continuing ,Disaster Planning ,Emergency Nursing ,medicine.disease_cause ,Plague (disease) ,complex mixtures ,Toxicology ,Tularemia ,medicine ,Humans ,Smallpox ,Intensive care medicine ,Francisella tularensis ,Bacteria ,biology ,business.industry ,Public health ,biology.organism_classification ,medicine.disease ,Bioterrorism ,Bacillus anthracis ,Hemorrhagic Fevers ,Emergency Medicine ,Clostridium botulinum ,Emergency Service, Hospital ,business - Abstract
Bioterrorism presents a real and omnipresent risk to public health throughout the world. More than 30 biological agents have been identified as possessing the potential to be deployed in a bioterrorist attack. Those that have been determined to be of the greatest concern and possess the greatest potential of use in this arena are known as the Category A agents: Bacillus anthracis (anthrax); Variola major (smallpox); Yersinia pestis (plague); Francisella tularensis (tularemia); viral hemorrhagic fevers; and Clostridium botulinum toxin (botulism toxin). Although the Centers for Disease Control and Prevention utilizes surveillance systems to identify illnesses, the weight of diagnosing, effectively treating, and notifying the appropriate public health officials lies squarely on the shoulders of emergency care personnel. Part I of this two-part review will focus on the clinical presentation and treatment of anthrax, plague, and tularemia. The subsequent Part II of this review will discuss smallpox, viral hemorrhagic fevers, botulism toxin, and the provision of mass prophylaxis.
- Published
- 2014
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.